Actinium Pharmaceuticals Investor Relations Material

Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted radiotherapies. These therapies are designed to deliver cancer-killing radiation to patients with high unmet medical needs, particularly in oncology and hematology. Actinium's lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal clinical trial targeting elderly patients with relapsed or refractory acute myeloid leukemia for bone marrow transplant conditioning. Actinium Pharmaceuticals Inc. is based in New York, New York, and its shares are listed on the NYSE.